Title:
PD-1 VARIANT AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/236954
Kind Code:
A1
Abstract:
The present invention relates to a PD-1 variant and the use thereof. Specifically, the PD-1 variant of the present invention can bind to PD-L1 with high affinity, but does not bind to one or more anti-PD-1 monoclonal antibodies, and preferably does not bind to at least two anti-PD-1 monoclonal antibodies. The present invention also relates to a fusion protein comprising the PD-1 variant. The present invention further relates to a coding nucleic acid molecule of the PD-1 variant and the fusion protein, and the use.
More Like This:
Inventors:
GU WEIYUE (CN)
GAO BIN (CN)
MEI XIAOWEI (CN)
LI XUELONG (CN)
GAO BIN (CN)
MEI XIAOWEI (CN)
LI XUELONG (CN)
Application Number:
PCT/CN2023/098627
Publication Date:
December 14, 2023
Filing Date:
June 06, 2023
Export Citation:
Assignee:
CHINEO MEDICAL TECH CO LTD (CN)
International Classes:
C07K14/705; A61K38/17; A61P35/00; C07K19/00; C12N5/10; C12N15/12; C12N15/62; C12N15/63
Foreign References:
| CN108794619A | 2018-11-13 | |||
| CN108384795A | 2018-08-10 | |||
| CN109311981A | 2019-02-05 |
Other References:
ESZTER LÁZÁR-MOLNÁR ET AL.: "Structure-Guided Development of a High-Affinity Human Programmed Cell Death-1: Implications for Tumor Immunotherapy", EBIOMEDICINE, vol. 17, 17 March 2017 (2017-03-17), XP055796241, DOI: 10.1016/j.ebiom.2017.02.004
LIU, HAO: "Design and Optimization of High Affinity Antagonists against PD-1 Receptor", MEDICINE AND HEALTH SCIENCES, CHINESE MASTER'S THESES FULL-TEXT DATABASE (ELECTRONIC JOURNALS), 15 January 2020 (2020-01-15)
LIU, HAO: "Design and Optimization of High Affinity Antagonists against PD-1 Receptor", MEDICINE AND HEALTH SCIENCES, CHINESE MASTER'S THESES FULL-TEXT DATABASE (ELECTRONIC JOURNALS), 15 January 2020 (2020-01-15)
Attorney, Agent or Firm:
IPFAITH PARTNERS (CN)
Download PDF: